Scientists have developed a new protein risk score to predict the chances of death for persons with heart failure.
Heart failure is a complex clinical syndrome with high
mortality rates, the researchers said.
Current risk approaches that capture the biological
complexity of the heart failure and show clinical utility are limited, they
said.
High-throughput proteomics -- a technique for
large-scale protein characterisation -- could improve risk prediction, but its
use in clinical practice to guide the management of patients with heart failure
depends on evidence of clinical benefit.
The researchers from the National Institutes of Health
in the US developed and validated the protein risk score to stratify mortality
risk in persons with heart failure using a community-based group of 7,289
plasma proteins in 1,351 patients with heart failure.
In the research, published in the journal Annals of
Internal Medicine, 38 unique proteins were selected for the risk score.
The protein risk score reclassified mortality risk and
showed greater clinical utility compared with the clinical model, the
researchers said.
These findings foreshadow the
clinical utility of large-scale proteomic assays for precision risk prediction
in heart failure, they said.
The researchers said this tool
may help clinicians select patients with advanced heart failure, at
particularly high risk for adverse outcomes, that should be considered for
mechanical circulatory support or transplantation.
The team noted that the participants were
predominantly of European ancestry, potentially limiting the generalisability
of the findings to different patient populations.
Further studies are needed to prospectively evaluate
the score's performance in diverse populations and determine risk thresholds
for interventions, they added.
No comments:
Post a Comment